IL239339A0 - Therapeutic 47cd antibodies - Google Patents

Therapeutic 47cd antibodies

Info

Publication number
IL239339A0
IL239339A0 IL239339A IL23933915A IL239339A0 IL 239339 A0 IL239339 A0 IL 239339A0 IL 239339 A IL239339 A IL 239339A IL 23933915 A IL23933915 A IL 23933915A IL 239339 A0 IL239339 A0 IL 239339A0
Authority
IL
Israel
Prior art keywords
antibodies
therapeutic
Prior art date
Application number
IL239339A
Other languages
English (en)
Hebrew (he)
Original Assignee
Vasculox Inc
William A Frazier
Pamela T Manning
Gerhard Frey
Hwai Wen Chang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasculox Inc, William A Frazier, Pamela T Manning, Gerhard Frey, Hwai Wen Chang filed Critical Vasculox Inc
Publication of IL239339A0 publication Critical patent/IL239339A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL239339A 2012-12-12 2015-06-10 Therapeutic 47cd antibodies IL239339A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261736301P 2012-12-12 2012-12-12
US201361833691P 2013-06-11 2013-06-11
PCT/US2013/074766 WO2014093678A2 (en) 2012-12-12 2013-12-12 Therapeutic cd47 antibodies

Publications (1)

Publication Number Publication Date
IL239339A0 true IL239339A0 (en) 2015-07-30

Family

ID=50935081

Family Applications (1)

Application Number Title Priority Date Filing Date
IL239339A IL239339A0 (en) 2012-12-12 2015-06-10 Therapeutic 47cd antibodies

Country Status (16)

Country Link
US (4) US20140363442A1 (enExample)
EP (1) EP2931751B1 (enExample)
JP (1) JP6572131B2 (enExample)
KR (1) KR20150093770A (enExample)
CN (1) CN105102479B (enExample)
AU (1) AU2013359167B2 (enExample)
BR (1) BR112015013431A2 (enExample)
CA (1) CA2894439A1 (enExample)
ES (1) ES2786083T3 (enExample)
HK (1) HK1216647A1 (enExample)
IL (1) IL239339A0 (enExample)
MX (1) MX2015007446A (enExample)
PH (1) PH12015501318A1 (enExample)
RU (1) RU2015122228A (enExample)
SG (1) SG11201504469XA (enExample)
WO (2) WO2014093678A2 (enExample)

Families Citing this family (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5547656B2 (ja) 2008-01-15 2014-07-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７によって媒介される食作用を操作するための方法
HK1216647A1 (zh) 2012-12-12 2016-11-25 Vasculox Inc. 治疗性cd47抗体
US9221908B2 (en) 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
HUE047221T2 (hu) 2012-12-17 2020-04-28 Trillium Therapeutics Inc A CD47+ kóros sejtek kezelése SIRP alfa-FC fúziókkal
ES2931337T3 (es) * 2014-07-31 2022-12-28 Univ Western Australia Un método para la identificación de combinaciones de inmunoterapia-fármacos usando un enfoque de red
CA2964173A1 (en) * 2014-10-10 2016-04-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to eliminate cancer stem cells by targeting cd47
WO2016081423A1 (en) * 2014-11-18 2016-05-26 Janssen Pharmaceutica Nv Cd47 antibodies, methods, and uses
TR201903891T4 (tr) 2014-12-05 2019-04-22 Regeneron Pharma Bir insanlaştırılmış farklılaşma kümesi 47 genine sahip olan insan dışı hayvanlar.
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
TWI719966B (zh) * 2015-03-04 2021-03-01 美商索倫多醫療公司 結合ｃｄ４７之抗體治療劑
CN104804093A (zh) * 2015-05-27 2015-07-29 江苏春申堂药业有限公司 一种针对cd47的单域抗体
PL3341015T5 (pl) * 2015-08-26 2024-04-08 The Board Of Trustees Of The Leland Stanford Junior University Zwiększona deplecja komórek docelowych z blokadą cd47 i immunologicznym agonistą kostymulatorowym
WO2017044859A1 (en) * 2015-09-10 2017-03-16 Affigen, Inc. Sequencing-directed selection of tumor theranostics
CN108348589B (zh) 2015-09-18 2022-09-23 安驰肿瘤公司 治疗性cd47抗体
CA2999277A1 (en) 2015-09-21 2017-03-30 Surface Oncology, Inc. Anti-cd47 antibodies and methods of use
ES2988976T3 (es) 2015-11-27 2024-11-22 Cartherics Pty Ltd Células modificadas genéticamente y usos de estas
CN108925136B (zh) 2015-12-02 2022-02-01 斯特赛恩斯公司 特异于糖基化的btla（b和t淋巴细胞衰减因子）的抗体
KR102472087B1 (ko) 2016-01-11 2022-11-29 포티 세븐, 인코포레이티드 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체
KR102833922B1 (ko) * 2016-01-21 2025-07-15 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 면역조절제의 조합물에 의한 암의 치료
US20190091290A1 (en) * 2016-04-15 2019-03-28 Trillium Therapeutics Inc. Macrophage stimulation in cd47 blockade therapy
CN106084052B (zh) * 2016-06-17 2019-12-27 长春金赛药业股份有限公司 抗cd47单克隆抗体及其应用
US12344669B2 (en) 2016-06-17 2025-07-01 Changchun Genescience Pharmaceutical Co., Ltd. Anti-CD47 monoclonal antibody and use thereof
CN106117354B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗CD47的全分子IgG抗体及其应用
EP3487522A4 (en) 2016-07-19 2020-04-01 Teva Pharmaceuticals Australia Pty Ltd Anti-cd47 combination therapy
KR102423086B1 (ko) 2016-10-20 2022-07-20 아이-맵 바이오파마 유에스 리미티드 새로운 cd47 단일클론 항체 및 그 용도
EP3529276A4 (en) * 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
WO2018081897A1 (en) 2016-11-03 2018-05-11 Trillium Therapeutics Inc. Enhancement of cd47 blockade therapy by proteasome inhibitors
CN108779179B (zh) * 2016-11-28 2022-02-08 江苏恒瑞医药股份有限公司 Cd47抗体、其抗原结合片段及其医药用途
EP3345924A1 (en) * 2017-01-10 2018-07-11 Universität Duisburg-Essen Use of cd47 antibodies
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US11267885B2 (en) 2017-01-26 2022-03-08 Zlip Holding Limited CD47 antigen binding unit and uses thereof
CN110612309A (zh) * 2017-03-27 2019-12-24 细胞基因公司 用于降低免疫原性的方法和组合物
CN110958888A (zh) * 2017-03-28 2020-04-03 延龄草治疗公司 Cd47阻断疗法
WO2019014398A1 (en) 2017-07-11 2019-01-17 Actym Therapeutics, Inc. MODIFIED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF
NZ761568A (en) * 2017-08-02 2022-11-25 Phanes Therapeutics Inc Anti-cd47 antibodies and uses thereof
AU2018316742B2 (en) 2017-08-18 2025-04-10 Centessa Pharmaceuticals (Uk) Limited Binding agents
CN109422811A (zh) * 2017-08-29 2019-03-05 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
EA039662B1 (ru) 2017-10-03 2022-02-24 Закрытое Акционерное Общество "Биокад" Антитела, специфичные к cd47 и pd-l1
RU2698048C2 (ru) 2017-10-03 2019-08-21 Закрытое Акционерное Общество "Биокад" МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
ES2932286T3 (es) 2017-10-18 2023-01-17 Forty Seven Inc Terapia contra el cáncer de ovarios basada en agente anti-CD47
AU2018358004A1 (en) 2017-11-01 2020-05-28 Hummingbird Bioscience Pte. Ltd. CD47 antigen-binding molecules
WO2019090355A1 (en) * 2017-11-06 2019-05-09 Children's National Medical Center Cells expressing antibodies and methods of treatment using the same
WO2019084692A1 (en) * 2017-11-06 2019-05-09 Trillium Therapeutics Inc. Cd47 blockade with radiation therapy
MA51208A (fr) 2017-12-01 2020-10-07 Seattle Genetics Inc Anticorps (masqués) contre cd47 et leurs utilisations pour le traîtement du cancer
CN110144009B (zh) * 2018-02-14 2020-01-21 上海洛启生物医药技术有限公司 Cd47单域抗体及其用途
GB201804860D0 (en) 2018-03-27 2018-05-09 Ultrahuman Two Ltd CD47 Binding agents
CN110305212A (zh) 2018-03-27 2019-10-08 信达生物制药(苏州)有限公司 抗cd47抗体及其用途
WO2019200462A1 (en) * 2018-04-16 2019-10-24 Adaerata, Limited Partnership Methods of preventing or treating non-hematopoietic slamf7 positive and slamf7 negative cancers
CN108484770B (zh) * 2018-05-16 2020-11-13 武汉云克隆科技股份有限公司 重组大鼠抗小鼠cd4单克隆抗体，制备方法和应用
CN110538321B (zh) * 2018-05-29 2023-03-10 江苏恒瑞医药股份有限公司 一种cd47抗体药物组合物及其用途
CN112566662A (zh) * 2018-06-15 2021-03-26 阿库鲁斯生物科学公司 针对cd47的阻断抗体及其使用方法
CN110615841B (zh) * 2018-06-20 2022-01-04 瑞阳(苏州)生物科技有限公司 抗人cd47单克隆抗体及其应用
CN112673092B (zh) 2018-07-11 2024-03-29 阿克蒂姆治疗有限公司 工程化的免疫刺激性细菌菌株及其用途
US20210324075A1 (en) * 2018-08-13 2021-10-21 Arch Oncology, Inc. Therapeutic cd47 antibodies
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
TWI830774B (zh) 2018-08-31 2024-02-01 大陸商南京聖和藥業股份有限公司 抗cd47抗體及其應用
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
WO2020091596A1 (en) * 2018-10-29 2020-05-07 Umc Utrecht Holding B.V. Iga mediated killing of aberrant cells by cd47- sirpalpha checkpoint inhibition of neutrophils
WO2020097193A1 (en) 2018-11-06 2020-05-14 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
US20220017615A1 (en) * 2018-12-03 2022-01-20 Shanghai Pharmaexplorer Co., Ltd. Cd47 antibody, preparation method therefor and uses thereof
JP2022523543A (ja) 2019-03-06 2022-04-25 ジエンス ヘンルイ メデイシンカンパニー リミテッド 二機能性融合タンパク質及びその医薬的使用
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
WO2020247820A1 (en) 2019-06-07 2020-12-10 ALX Oncology Inc. Methods and reagents for reducing the interference of drugs that bind cd47 in serological assays
WO2020253785A1 (en) * 2019-06-19 2020-12-24 Lepu Biopharma Co., Ltd. Anti-cd47 antibodies and uses thereof
JP7317148B2 (ja) * 2019-06-19 2023-07-28 レプ バイオファーマ カンパニー リミテッド 抗ｃｄ４７抗体およびその使用
US11795210B2 (en) 2019-07-16 2023-10-24 Gilead Sciences, Inc. HIV vaccines and methods of making and using
EP4008727A4 (en) * 2019-07-30 2024-01-17 Akeso Biopharma, Inc. ANTI-HUMAN P40 PROTEIN DOMAIN ANTIBODIES AND USE THEREOF
MX2022002613A (es) 2019-09-03 2022-06-02 Myeloid Therapeutics Inc Metodos y composiciones para la integracion del genoma.
PH12022550489A1 (en) * 2019-09-03 2022-12-12 Akeso Biopharma Inc Anti-cd47 monoclonal antibody and use thereof
PL4045083T3 (pl) 2019-10-18 2024-05-13 Forty Seven, Inc. Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej
AU2020372522B2 (en) * 2019-10-25 2024-08-15 WuXi Biologics Ireland Limited Novel anti-CD47 antibodies and uses thereof
CN114599392A (zh) 2019-10-31 2022-06-07 四十七公司 基于抗cd47和抗cd20的血癌治疗
US20230042316A1 (en) * 2019-11-20 2023-02-09 Abvision, Inc. Monoclonal antibodies that target human cd47 protein
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
MX2022007598A (es) 2019-12-20 2022-09-23 Instil Bio Uk Ltd Dispositivos y métodos para el aislamiento de linfocitos infiltrantes de tumores y usos de los mismos.
US11845723B2 (en) 2019-12-24 2023-12-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CR20220396A (es) 2020-02-14 2022-11-14 Jounce Therapeutics Inc Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
WO2021190441A1 (zh) * 2020-03-23 2021-09-30 倍而达药业（苏州）有限公司 Cd47/人源化cd47抗体或其抗原结合片段、免疫活性片段及应用
CA3172449A1 (en) 2020-03-27 2021-09-30 Erik Hans MANTING Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
IL296829A (en) * 2020-04-02 2022-11-01 Chia Tai Tianqing Pharmaceutical Group Co Ltd Antigen-binding polypeptide binding to cd47, and use thereof
CN111635459B (zh) * 2020-06-27 2021-01-15 广东赛尔生物科技有限公司 抗cd47抗体及其在治疗癌症中的应用
KR20230033647A (ko) 2020-06-30 2023-03-08 멘두스 비.브이. 난소암 백신에서 백혈병 유래 세포의 용도
US20240016787A1 (en) 2020-11-03 2024-01-18 Rdiscovery, LLC Methods for treatment of cancer and phagocytosis-deficiency related diseases
JP2023549140A (ja) 2020-11-04 2023-11-22 マイエロイド・セラピューティクス，インコーポレーテッド 操作されたキメラ融合タンパク質組成物およびその使用方法
KR20230142828A (ko) * 2020-11-04 2023-10-11 더 트러스티즈 오브 다트마우스 칼리지 허혈성 및/또는 재관류 손상의 치료/예방을 위한 vista 작용제
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays
WO2022130016A1 (en) 2020-12-18 2022-06-23 Instil Bio (Uk) Limited Tumor infiltrating lymphocytes and anti-cd47 therapeutics
EP4296282A4 (en) * 2021-02-19 2025-02-26 SHAPERON Inc. SINGLE DOMAIN ANTIBODIES AGAINST CD47 AND USE THEREOF
KR20230157388A (ko) 2021-03-12 2023-11-16 멘두스 비.브이. 백신접종의 방법 및 cd47 차단의 용도
CN112979764B (zh) * 2021-03-26 2022-08-02 复旦大学附属中山医院 特异结合人cd47分子的多肽及其用途
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
CA3218780A1 (en) 2021-05-11 2022-11-17 Daniel Getts Methods and compositions for genomic integration
CN117377671A (zh) 2021-06-23 2024-01-09 吉利德科学公司 二酰基甘油激酶调节化合物
CA3222277A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
AU2022297367B2 (en) 2021-06-23 2025-04-10 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
IL309378A (en) 2021-06-23 2024-02-01 Gilead Sciences Inc Diacylglyercol kinase modulating compounds
WO2023076983A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
JP2024545193A (ja) 2021-12-22 2024-12-05 ギリアード サイエンシーズ， インコーポレイテッド Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用
AU2022419982A1 (en) 2021-12-22 2024-06-06 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2023159220A1 (en) * 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies
EP4493554A1 (en) 2022-03-17 2025-01-22 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
EP4499146A1 (en) 2022-03-24 2025-02-05 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
AU2023256670A1 (en) 2022-04-21 2024-10-17 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY
AU2023409398A1 (en) 2022-12-22 2025-06-05 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
AU2024259556A1 (en) 2023-04-21 2025-10-23 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
US20250042922A1 (en) 2023-06-30 2025-02-06 Gilead Sciences, Inc. Kras modulating compounds
TW202519517A (zh) 2023-07-26 2025-05-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
WO2025024663A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
WO2025054347A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Kras g12d modulating compounds
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN120648654A (zh) * 2024-03-13 2025-09-16 深圳太力生物技术有限责任公司 重组细胞的制备方法、重组细胞及其应用
US20250376484A1 (en) 2024-05-21 2025-12-11 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE143052T1 (de) 1986-07-07 1996-10-15 Centocor Inc Chimärisches murine-mensch-immunoglobulin, spezifisch für tumorassoziertes 17-1a antigen
DE69839492D1 (de) 1997-09-11 2008-06-26 Chugai Pharmaceutical Co Ltd Monoklonale antikörper zur apoptosis-induzierung
US7531643B2 (en) 1997-09-11 2009-05-12 Chugai Seiyaku Kabushiki Kaisha Monoclonal antibody inducing apoptosis
CA2226962A1 (en) * 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
DE19813759C1 (de) 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort
US7696325B2 (en) 1999-03-10 2010-04-13 Chugai Seiyaku Kabushiki Kaisha Polypeptide inducing apoptosis
WO2000053634A1 (en) 1999-03-10 2000-09-14 Chugai Seiyaku Kabushiki Kaisha Single-stranded fv inducing apoptosis
JP2004513066A (ja) * 1999-06-21 2004-04-30 インカイン　ファーマシューティカル　カンパニー，インコーポレイティド アンジオシジン：ｃｙｓ−ｓｅｒ−ｖａｌ−ｔｈｒ−ｃｙｓ−ｇｌｙ特異的腫瘍細胞付着受容体
US20010041670A1 (en) * 1999-12-06 2001-11-15 Ronit Simantov Thrombospondin-binding region of histidine-rich glycoprotein and method of use
US20050074457A1 (en) 2001-12-12 2005-04-07 Adeela Kamal Assays and implements for determining and modulating hsp90 binding activity
US20040213792A1 (en) 2003-04-24 2004-10-28 Clemmons David R. Method for inhibiting cellular activation by insulin-like growth factor-1
US8101719B2 (en) 2003-11-11 2012-01-24 Chugai Seiyaku Kabushiki Kaisha Humanized anti-CD47 antibody
GT200500255A (es) 2004-09-10 2006-04-10 Anticuerpos anti-5ta humanizados y conjugados anticuerpo anti-5ta/calicheamicina
JP2007008895A (ja) 2005-07-04 2007-01-18 Chugai Pharmaceut Co Ltd 抗ｃｄ４７抗体とインテグリンリガンドとの併用
US7514229B2 (en) 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
PL1994055T3 (pl) 2006-03-10 2015-02-27 Wyeth Llc Przeciwciała anty-5T4 i ich zastosowanie
WO2008043072A2 (en) 2006-10-05 2008-04-10 Biogen Idec Inc. Cd80 antagonists for treating neoplastic disorders
CA3163418A1 (en) * 2006-10-06 2008-05-22 Jeffrey S. Isenberg Prevention of tissue ischemia, related methods and compositions
JP5547656B2 (ja) 2008-01-15 2014-07-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Ｃｄ４７によって媒介される食作用を操作するための方法
AU2014201010B2 (en) 2008-01-15 2016-03-03 The Board Of Trustees Of The Leland Stanford Junior University Methods for manipulating phagocytosis mediated by CD47
EP3722317B1 (en) 2008-01-15 2024-08-07 The Board of Trustees of the Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
BRPI0907718A2 (pt) 2008-02-11 2017-06-13 Curetech Ltd método para tratar um tumor, método para melhorar a tolerabilidade a pelo menos um agente quimiterápico, método para aumentar a sobrevida de um indivíduo que tem um tumor, método para reduzir ou prevenir recidiva tumoral, uso de um anticorpo monoclonal humanizado ou seu fragmento e anticorpo monoclonal humanizado ou seu fragmento
KR101604515B1 (ko) 2008-03-14 2016-03-17 알러간, 인코포레이티드 면역-기반 보툴리눔 독소 세로타입 ａ 활성 검정
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
CA2732102C (en) 2008-08-07 2018-01-02 Jeffrey S. Isenberg Radioprotectants targeting thrombospondin-1 and cd47
CA3057650A1 (en) 2009-09-15 2011-03-24 Irving L. Weissman Synergistic anti-cd47 therapy for hematologic cancers
WO2011083141A2 (en) 2010-01-08 2011-07-14 Ablynx Nv Method for generation of immunoglobulin sequences by using lipoprotein particles
EP2526118A4 (en) 2010-01-21 2013-11-13 Immunogen Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF EGG CANCER
DK2569013T3 (da) * 2010-05-14 2017-02-13 Univ Leland Stanford Junior Humaniserede og kimære monoklonale antistoffer til cd47
US9243057B2 (en) 2010-08-31 2016-01-26 The Regents Of The University Of California Antibodies for botulinum neurotoxins
WO2012088309A1 (en) 2010-12-21 2012-06-28 The Board Of Trustees Of The Leland Stanford Junior University Therapeutic and diagnostic methods for manipulating phagocytosis through calreticulin and low density lipoprotein-related receptor
EP2812443B1 (en) * 2012-02-06 2019-05-29 Inhibrx, Inc. Cd47 antibodies and methods of use thereof
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
SG10201704992SA (en) 2012-06-21 2017-07-28 Compugen Ltd Lsr antibodies, and uses thereof for treatment of cancer
CN105121467B (zh) 2012-12-03 2019-07-05 诺夫免疫股份有限公司 抗cd47抗体及其使用方法
US9221908B2 (en) * 2012-12-12 2015-12-29 Vasculox, Inc. Therapeutic CD47 antibodies
HK1216647A1 (zh) 2012-12-12 2016-11-25 Vasculox Inc. 治疗性cd47抗体
EA036963B1 (ru) 2013-02-06 2021-01-20 Инхибркс, Инк. Применение эпитопа cd47 для получения антитела к cd47
AU2014238105B2 (en) 2013-03-15 2018-11-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for achieving therapeutically effective doses of anti-CD47 agents
CN103665165B (zh) 2013-08-28 2016-02-24 江苏匡亚生物医药科技有限公司 一种靶向人CD47-SIRPα信号通路的双特异性抗体及其制备方法和用途
WO2015103139A1 (en) 2013-12-31 2015-07-09 Development Center For Biotechnology Anti-vegf antibodies and use thereof
CN108348589B (zh) 2015-09-18 2022-09-23 安驰肿瘤公司 治疗性cd47抗体
US10946042B2 (en) 2015-12-01 2021-03-16 The Trustees Of The University Of Pennsylvania Compositions and methods for selective phagocytosis of human cancer cells
EP3529276A4 (en) 2016-10-21 2020-06-17 Arch Oncology, Inc. CD47 THERAPEUTIC ANTIBODIES
SG11201908602UA (en) 2017-03-22 2019-10-30 Arch Oncology Inc Combination therapy for the treatment of solid and hematological cancers
US20190309066A1 (en) 2017-03-22 2019-10-10 Arch Oncology, Inc. Combination therapy for the treatment of solid and hematological cancers

Also Published As

Publication number Publication date
JP6572131B2 (ja) 2019-09-04
PH12015501318A1 (en) 2015-08-24
CN105102479A (zh) 2015-11-25
ES2786083T3 (es) 2020-10-08
CN105102479B (zh) 2019-06-28
CA2894439A1 (en) 2014-06-19
EP2931751B1 (en) 2020-02-05
WO2014093678A2 (en) 2014-06-19
KR20150093770A (ko) 2015-08-18
EP2931751A4 (en) 2016-07-13
MX2015007446A (es) 2015-12-07
AU2013359167B2 (en) 2018-08-23
SG11201504469XA (en) 2015-07-30
US20140363442A1 (en) 2014-12-11
RU2015122228A (ru) 2017-01-19
US10669336B2 (en) 2020-06-02
WO2014093678A3 (en) 2014-11-27
US10676524B2 (en) 2020-06-09
NZ708445A (en) 2020-10-30
HK1216647A1 (zh) 2016-11-25
US20150274826A1 (en) 2015-10-01
WO2015191861A1 (en) 2015-12-17
JP2016501892A (ja) 2016-01-21
EP2931751A2 (en) 2015-10-21
AU2013359167A1 (en) 2015-06-11
BR112015013431A2 (pt) 2017-11-14
US20180057592A1 (en) 2018-03-01
US20180051081A1 (en) 2018-02-22

Similar Documents

Publication Publication Date Title
IL239339A0 (en) Therapeutic 47cd antibodies
IL264558A (en) Anti–il–23p19 antibodies
ZA201407509B (en) Anti-fcrn antibodies
ZA201407897B (en) Protease-regulated antibodies
IL229254A0 (en) Therapeutic antibodies
ZA201409358B (en) Anti-siglec- 15 antibodies
ZA201407316B (en) Anti-fgfr2 antibody
SG10201709290XA (en) Anti-H7cr Antibodies
ZA201407079B (en) Cdr-modified anti-siglec-15 antibody
GB201220242D0 (en) Antibody
EP2804876A4 (en) NEW ANTIBODIES
EP2811018A4 (en) ANTI-BODY ANTI-sAPPß
IL235188A0 (en) Antibodies against c-pdgf
GB201209584D0 (en) Modified antibodies
ZA201308992B (en) Therapeutic antibodies
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations